CAUTION: When reading this news item please be aware that the RejuvenAir System is an Investigational device, limited by United States Federal law to investigational use only. Not for Sale in the United States of America.
CSA Medical Raises $53 Million in Series D Financing to Support PMA of the RejuvenAir System
TVM Capital Life Science and Yonjin Venture co-led the round, joined by a strong syndicate of existing investors BOSTON, Sept. 9, 2024 /PRNewswire/ — CSA Medical Inc., developer of The RejuvenAir® System, a Breakthrough Medical Device advancing the power of...
CSA Medical Announces Completion of Enrollment in Mechanism of Action Study utilizing the RejuvenAir® System for COPD Patients with Chronic Bronchitis
These results should provide the scientific proof behind the remodeling response and clinical improvements identified in earlier studies Boston, MA—May 12, 2021: CSA Medical, Inc., today announced ® that all subjects have been enrolled in the RejuvenAir System study...
CSA Medical, Inc. Announces Cooper University Health Care is the 20th Clinical Site to Join the SPRAY-CB Pivotal Study for the treatment of Chronic Bronchitis
Boston, MA –April 19, 2021: CSA Medical, Inc., today announced that Wissam Abouzgheib, MD, chief of pulmonary medicine at Cooper University Health Care, Camden, New Jersey, has joined the SPRAY-CB Study investigating a new device treatment for COPD with Chronic...
CSA Medical Announces Metered Cryospray with the RejuvenAir® System for the treatment of Chronic Bronchitis Featured at the 21st World Congress of Bronchology and Interventional Pulmonology
The RejuvenAir System is designed to address the underlying cause of COPD with Chronic Bronchitis and enable rejuvenative healing of the airways BOSTON, Nov. 23, 2020 — CSA Medical, Inc., today announced metered cryospray utilizing the RejuvenAir® System for the...